1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF ANEMIA TREATMENT DRUG MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL ANEMIA TREATMENT DRUG MARKET SNAPSHOT
3.2 GLOBAL ANEMIA TREATMENT DRUG MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL ANEMIA TREATMENT DRUG MARKET, BY TYPE
5.1 OVERVIEW
5.2 CHRONIC KIDNEY DISEASE RELATED ANEMIA
5.3 IRON DEFICIENCY ANEMIA
5.4 APLASTIC ANEMIA
5.5 SICKLE CELL ANEMIA
6 GLOBAL ANEMIA TREATMENT DRUG MARKET, BY GEOGRAPHY
6.1 NORTH AMERICA
6.1.1 MARKET DYNAMICS
6.1.1.1 DRIVERS
6.1.1.2 RESTRAINS
6.1.1.3 OPPORTUNITY
6.1.2 U.S.
6.1.3 CANADA
6.1.4 MEXICO
6.2 EUROPE
6.2.1 MARKET DYNAMICS
6.2.1.1 DRIVERS
6.2.1.2 RESTRAINS
6.2.1.3 OPPORTUNITY
6.2.2 U.K.
6.2.3 FRANCE
6.2.4 GERMANY
6.2.5 REST OF EUROPE
6.3 ASIA PACIFIC
6.3.1 MARKET DYNAMICS
6.3.1.1 DRIVERS
6.3.1.2 RESTRAINS
6.3.1.3 OPPORTUNITY
6.3.2 INDIA
6.3.3 CHINA
6.3.4 JAPAN
6.3.5 REST OF ASIA PACIFIC
6.4 MIDDLE EAST AND AFRICA
6.4.1 MARKET DYNAMICS
6.4.1.1 DRIVERS
6.4.1.2 RESTRAINS
6.4.1.3 OPPORTUNITY
6.4.2 SOUTH AFRICA
6.4.3 REST OF MIDDLE EAST AND AFRICA
6.5 LATIN AMERICA
6.5.1 MARKET DYNAMICS
6.5.1.1 DRIVERS
6.5.1.2 RESTRAINS
6.5.1.3 OPPORTUNITY
6.5.2 BRAZIL
6.5.3 REST OF LATIN AMERICA
7 COMPETATIVE LANDSCAPE
7.1 OVERVIEW
7.2 NEW PRODUCT LAUNCHES
8 GLOBAL ANEMIA TREATMENT DRUG MARKET, BY COMPANY
8.1 INTRODUCTION
8.2 BAYER AG
8.2.1 BUSINESS OVERVIEW
8.2.2 PRODUCTS & SERVICES
8.2.3 KEY STRATEGY
8.2.4 RECENT DEVELOPMENTS
8.2.5 SWOT ANALYSIS
8.3 ACCELERON PHARMA
8.3.1 BUSINESS OVERVIEW
8.3.2 PRODUCTS & SERVICES
8.3.3 KEY STRATEGY
8.3.4 RECENT DEVELOPMENTS
8.3.5 SWOT ANALYSIS
8.4 ELI LILLY
8.4.1 BUSINESS OVERVIEW
8.4.2 PRODUCTS & SERVICES
8.4.3 KEY STRATEGY
8.4.4 RECENT DEVELOPMENTS
8.4.5 SWOT ANALYSIS
8.5 REGEN BIOPHARMA
8.5.1 BUSINESS OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 KEY STRATEGY
8.5.4 RECENT DEVELOPMENTS
8.5.5 SWOT ANALYSIS
8.6 CELGENE CORPORATION
8.6.1 BUSINESS OVERVIEW
8.6.2 PRODUCTS & SERVICES
8.6.3 KEY STRATEGY
8.6.4 RECENT DEVELOPMENTS
8.6.5 SWOT ANALYSIS
8.7 FIBROGEN
8.7.1 BUSINESS OVERVIEW
8.7.2 PRODUCTS & SERVICES
8.7.3 KEY STRATEGY
8.7.4 RECENT DEVELOPMENTS
8.7.5 SWOT ANALYSIS
8.8 GLAXOSMITHKLINE PLC
8.8.1 BUSINESS OVERVIEW
8.8.2 PRODUCTS & SERVICES
8.8.3 KEY STRATEGY
8.8.4 RECENT DEVELOPMENTS
8.8.5 SWOT ANALYSIS
8.9 AKEBIA THERAPEUTICS
8.9.1 BUSINESS OVERVIEW
8.9.2 PRODUCTS & SERVICES
8.9.3 KEY STRATEGY
8.9.4 RECENT DEVELOPMENTS
8.9.5 SWOT ANALYSIS